Kurzfassung

Chronic hepatitis C virus (HCV) infection is a major reason for liver associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of direct antiviral agents in 2014, therapeutic efficacy improved dramatically, leading to higher response rates and shorter treatment duration.

Whether an effective antiviral HCV therapy results in an early inhibition of fibrogenesis or even fibrosis regression, as assessed by serum fibrosis markers and elastography, is...Chronic hepatitis C virus (HCV) infection is a major reason for liver associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of direct antiviral agents in 2014, therapeutic efficacy improved dramatically, leading to higher response rates and shorter treatment duration.

Whether an effective antiviral HCV therapy results in an early inhibition of fibrogenesis or even fibrosis regression, as assessed by serum fibrosis markers and elastography, is unknown.

Aim: To evaluate early changes of fibrosis in patients treated with sofosbuvir using panels of serum fibrosis markers and liver stiffness measurement (LSM)» weiterlesen» einklappen